Welcome to Algaurizin
Your data open doors to a world of insights
The biosimilar market is experiencing a "golden era" with 85 biologic patents expiring between 2025-2028
$72.29B
The global biosimilars market valued at $35.04 billion in 2025 and projected to reach $72.29 billion by 2035 at a 7.5% CAGR
7.5%
CAGR Growth Rate
$35.04B
Current Market Size
Interchangeable biosimilars achieve 35% market share within 12 months vs. 18% for standard biosimilars
The Humira Biosimilar Battle: AbbVie's response extends far beyond traditional patent litigation.
60%
Humira retains market share despite 10+ biosimilars
23%
Adalimumab biosimilar adoption rate
Payer Adoption Patterns:
35%
Commercial Plans
15%
Medicare
18
FDA Approvals (2024)
Key Insight: Biosimilar success depends more on market access strategy than clinical similarity. Interchangeable status drives 2.3x higher pharmacy substitution rates.
Biosimilar Market Intelligence Dashboard
$35.04B
2025 Market Value
+7.5% CAGR
72%
Humira Market Share
-5% vs. 2023
$200B+
Patent Cliff (2025-2030)
Opportunity
31%
Biosimilar Adoption
vs 90% generics
The global biosimilar market is experiencing unprecedented growth, driven by patent expirations of major biologics and increasing healthcare cost pressures. With over $200 billion in biologics facing patent expiration through 2030, the industry stands at a critical inflection point where biosimilar competition will fundamentally reshape pharmaceutical market dynamics.
Critical Market Insights
Humira Defense Strategy: AbbVie's citrate-free formulation and Unbroken Dose program have maintained 72% market share despite 10 biosimilars competing, demonstrating sophisticated originator defense tactics.
Payer Dynamics: Commercial payers show 35% biosimilar adoption versus only 15% in Medicare, highlighting the critical role of payer strategy in biosimilar market penetration.
Interchangeability Advantage: Interchangeable biosimilars achieve achieve 35% market share within 12 months versus 18% for non-interchangeable products, representing approximately $400M in additional revenue opportunity.
High-Value Pipeline Opportunities 2025-2026
Stelara (ustekinumab)
2025 patent expiry | $9.1B peak sales | Samsung Bioepis SB17 filed with FDA
Eylea (aflibercept)
2025 patent expiry | $5.9B peak sales | Coherus CHS-2020 positive Phase 3 data
Eliquis (apixaban)
2026 patent expiry | $11.8B current sales | 23 companies filed Paragraph IV challenges
Keytruda (pembrolizumab)
2028 patent expiry | $25B projected peak sales | Multiple developers in preparation phase
Adalimumab Market Evolution
Biosimilar Market Growth Projection
Data compiled from IQVIA Biosimilar Market Tracker Q2 2025, Samsung Bioepis reports, FDA Purple Book, company earnings calls, and multiple pharmaceutical market research sources. Market projections from Mordor Intelligence and MarketsandMarkets.
Your data empower us to give you the world.
Contact Info
213 Carnegie Center, Suite 2027 - Princeton, NJ 08540
(609) 644-4944
info@algaurizin.com